Clinical Issues in Severe AsthmaDebates and Discussions About New Upstream Treatment Avenues
Dinner/Registration: 6:30 pm-7:00 pm PT
Educational Session: 7:00 pm-8:30 pm PT
Dinner will be provided.
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca
This Industry Program presentation at the ATS 2022 International Conference is open to all ATS 2022 International Conference attendees.
The educational design of this activity addresses the needs of pulmonologists, clinical immunologists, and other specialist clinicians who treat patients with severe asthma.
This live Clinical Issues™in Severe Asthma program has been designed to engage and educate attendees while promoting critical thinking. Using a discussion-based format, expert faculty will examine various sides of key clinical issues—including the role of the epithelium in asthma development and progression, mechanisms underlying asthma phenotypes, the rationale for therapies that target disease upstream of the common T2-high and T-low pathways, recent clinical trial evidence for newer pharmacotherapies, and the interpretation and use of biomarkers within management. This program will also expand on attendee engagement by incorporating the clinical experience and unique challenges of the broader asthma community via results from previously deployed learner surveys. In this way, Clinical Issues™ in Severe Asthma intends to deliver not only expert recommendations but learner insights for optimizing severe asthma management across diverse patient populations.
Upon completion of this activity, the participant should be better able to:
- Describe severe asthma pathophysiology, including the upstream role of TSLP and implications for treatment
- Discuss the mechanisms of action and clinical profiles of new targeted therapies for severe asthma, including those targeting TSLP
- Construct treatment regimens for patients with severe asthma with new targeted agents based on symptoms, disease presentation, patient preferences, and shared clinical decision making
7:00 PM - 7:10 PM Faculty Welcome and Preactivity Questionnaire
7:10 PM – 7:30 PM Progressing Our Understanding of Asthma Pathophysiology
7:30 PM – 7:50 PM New Targeted Therapies for Severe Asthma
7:50 PM – 8:10 PM The Value of Biomarkers Within Treatment Monitoring
8:10 PM – 8:20 PM Choose-a-Topic (Attendee Polling)
8:20 PM – 8:30 PM Postactivity Questionnaire and Q&A Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.5 contact hour(s) (which includes 0.2 hour(s) of pharmacology).
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Julie Krauss prior to the live event at firstname.lastname@example.org
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or email@example.com.
Clinical Issues in Severe Asthma